Replies to post #182735 on Biotech Values

[DewDiligence]

Any thoughts on JNJ's pricing comments? It might be able to keep some sales if [Olysio] used with Sovaldi and priced at $10-20K, but I really doubt that they would do that. It would also affect ABBV sales if they do.

I don’t think there will be demand for a multi-vendor regimen that doesn’t even offer the lowest price when there are two excellent single-vendor regimens to choose from.